<DOC>
	<DOCNO>NCT00411138</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , paclitaxel , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy radiation therapy surgery may kill tumor cell remain surgery . It yet know whether give chemotherapy together radiation therapy effective give radiation therapy alone treat endometrial cancer . PURPOSE : This randomized phase III trial study chemotherapy radiation therapy see well work compare radiation therapy alone treat patient high-risk , stage I , stage II , stage III endometrial cancer .</brief_summary>
	<brief_title>Randomized Trial Radiation Therapy With Without Chemotherapy Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival failure-free survival patient high-risk stage IB-III endometrial carcinoma treat concurrent chemoradiotherapy follow adjuvant chemotherapy v pelvic radiotherapy alone . Secondary - Compare rate pelvic distant recurrence , severe ( grade 3 4 ) treatment-related toxicity , quality life patient treat regimen . OUTLINE : This multicenter , prospective , open-label , randomize , control study . Patients stratify accord participate group ( DGOG vs UK NCRI v NCIC CTG v MaNGO v Unicancer ) , type surgery ( total abdominal hysterectomy bilateral salpingo-oophorectomy [ TAH-BSO ] v TAH-BSO plus lymphadenectomy v laparoscopic hysterectomy [ TLH-BSO ] v TLH-BSO plus lymphadenectomy ) , stage ( IA vs IB v II v III ) , histological type ( endometrioid carcinoma v serous clear cell carcinoma ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive external-beam pelvic radiotherapy 5 day week 6 week , combine cisplatin IV day 1 22 . Patients cervical involvement undergo vaginal brachytherapy boost . At least 3 week completion chemoradiotherapy , patient undergo adjuvant chemotherapy comprise paclitaxel IV carboplatin IV day 1 . Adjuvant chemotherapy repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients undergo external-beam pelvic radiotherapy ( vaginal brachytherapy alone case cervical involvement ) arm I . Quality life assess baseline , completion radiotherapy , completion chemotherapy , 6 month , year 5 year . After completion study therapy , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 670 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm endometrial carcinoma , one follow postoperative FIGO 2009 stage grade : 1. stage IA invasion , grade 3 document LVSI 2. stage IB grade 3 3. stage II 4. stage IIIA IIIC ; IIIB parametrial invasion 5. stage IA ( invasion ) , IB , II , III serous clear cell histology WHOperformance status 02 WBC ≥ 3.0 x 109/L . Platelets ≥ 100 x 109/L . Bilirubin ≤ 1.5 x UNL ASAT/ALAT ≤ 2.5 x UNL Written inform consent Exclusion criterion : Uterine sarcoma ( include carcinosarcoma ) Previous malignancy ( except nonmelanomatous skin cancer ) &lt; 10 yr Previous pelvic radiotherapy Hormonal therapy chemotherapy tumor Macroscopic stage II Wertheim type hysterectomy ( eligible stage II grade 3 stage III pathology ) Prior diagnosis Crohn 's disease ulcerative colitis Residual macroscopic tumor surgery Creatinine clearance ≤ 60 ml/min ( Cockroft ) ≤ 50 ml/min ( EDTA clearance , measure creatinine clearance ) Impaired cardiac function , prohibit infusion large amount fluid cisplatin therapy Peripheral Neuropathy &gt; = grade 2 Hearing impairment &gt; = grade 3 , bear deaf</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>endometrial clear cell carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>stage IA grade 3 endometrial carcinoma</keyword>
	<keyword>stage IB endometrial carcinoma</keyword>
	<keyword>stage IIIA endometrial carcinoma</keyword>
	<keyword>stage IIIB endometrial carcinoma</keyword>
	<keyword>stage IIIC endometrial carcinoma</keyword>
</DOC>